Sign In
Buy PRF
$54.46
-0.0200 (-0.0367%)
At Close: Jul 13, 2026
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Util
No Summer Solstice for ETFs: June Records Cap Off a Blockbuster First Half
07:08am, Monday, 06'th Jul 2026
The arrival of June usually signals a seasonal slowdown for many people, but our ETF industry clearly missed the memo. Instead of heading to the beach or stopping to watch the World Cup, the ETF ecosy
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
08:30am, Thursday, 25'th Jun 2026
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market dec
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with
Should Invesco RAFI US 1000 ETF (PRF) Be on Your Investing Radar?
07:21am, Monday, 25'th May 2026
Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco RAFI US 1000 ETF (PRF) is a passively managed exchange traded fund launched on December 19, 2005.
Is Invesco RAFI US 1000 ETF (PRF) a Strong ETF Right Now?
07:21am, Friday, 15'th May 2026
A smart beta exchange traded fund, the Invesco RAFI US 1000 ETF (PRF) debuted on 12/19/2005, and offers broad exposure to the Style Box - Large Cap Value category of the market.
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
08:00am, Tuesday, 28'th Apr 2026
Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF'
Evergreen Capital Management LLC Has $1.30 Million Holdings in Invesco RAFI US 1000 ETF $PRF
03:58am, Friday, 24'th Apr 2026
Evergreen Capital Management LLC lessened its stake in Invesco RAFI US 1000 ETF (NYSEARCA:PRF) by 26.9% in the fourth quarter, according to the company in its most recent disclosure with the Securitie
Invesco RAFI US 1000 ETF (NYSEARCA:PRF) Hits New 52-Week High – Still a Buy?
02:33am, Sunday, 19'th Apr 2026
Invesco RAFI US 1000 ETF (NYSEARCA:PRF - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $50.45 and last traded at $50.38, with a volum
7 Dividend ETFs Built to Survive a Recession and Pay You Through It
01:14pm, Friday, 10'th Apr 2026
Recession probability indicators are flashing caution. The yield curve has spent extended periods inverted, the Conference Board's Leading Economic Index has posted consecutive monthly declines, and m
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2
4 ETFs That Beat the S&P 500 by Ignoring Market Cap Entirely
08:20am, Thursday, 26'th Mar 2026
Market-cap weighting has a structural flaw that most investors overlook: it automatically overweights whatever has already gotten expensive.
Should Invesco RAFI US 1000 ETF (PRF) Be on Your Investing Radar?
07:21am, Tuesday, 24'th Mar 2026
Launched on December 19, 2005, the Invesco RAFI US 1000 ETF (PRF) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity marke
TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced a commercial collaboration agreement with Blade Ranger Ltd.
